卵巢癌放射治疗的生存分析：一项监测、流行病学和最终结果（SEER）数据库分析
Survival Analysis of Radiation Therapy in Ovarian Cancer: A SEER Database Analysis.
作者信息
Yu Lushi, Gong Hongyun, Li Qian, Ren Honggang, Wang Yi, He Haihua, Li Tian, Song Qibin
机构信息
Cancer Center, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei, China.
School of Basic Medicine Fourth Military Medical University/Air Force Medical University, Xi'an 710032, Shanxi, China.
出版信息
J Oncol. 2021 Feb 11;2021:8849039. doi: 10.1155/2021/8849039. eCollection 2021.
RESULTS
A total of 20031 ovarian cancer patients were included, with 291 (1.45%) patients who received radiotherapy. The median overall survival (OS) in patients who received radiotherapy was shorter than which in patients without radiotherapy (23 vs. 75 months, < 0.001). The Elderly, nonepithelial pathology, advanced American Joint Committee on Cancer (AJCC) stage, elevated level of CA125, and receiving radiotherapy were risk predictors to survival in both multivariable analyses before and after PSM. Among 11872 patients with III/IV stage, the radiotherapy group also showed a significantly worse prognosis (median OS: 19 vs. 44 months in patients without radiotherapy, < 0.001). Consistent results were observed in stratification analyses on pathology and stage among patients with III/IV stage.
CONCLUSIONS
For patients with ovarian cancer, radiotherapy was associated with a poor prognosis regardless of pathology or stage. Considering this is a retrospective study, future studies concerning radiotherapy combination with other new agents in ovarian cancer are needed.
结果
共纳入20031例卵巢癌患者，其中291例（1.45%）接受了放疗。接受放疗患者的中位总生存期（OS）短于未接受放疗的患者（23个月对75个月，P<0.001）。在倾向得分匹配（PSM）前后的多变量分析中，年龄较大、非上皮性病理类型、美国癌症联合委员会（AJCC）晚期、CA125水平升高以及接受放疗均为生存的风险预测因素。在11872例III/IV期患者中，放疗组的预后也显著更差（中位OS：接受放疗患者为19个月，未接受放疗患者为44个月，P<0.001）。在III/IV期患者的病理和分期分层分析中观察到了一致的结果。
结论
对于卵巢癌患者，无论病理类型或分期如何，放疗均与预后不良相关。鉴于本研究为回顾性研究，未来需要开展关于卵巢癌放疗联合其他新药的研究。
Zotero 插件